Skip to main content
. 2015 Nov 24;15:929. doi: 10.1186/s12885-015-1911-8

Fig. 3.

Fig. 3

Progression-free survival as a function of F/B in ER+ recurrent breast cancer patients treated with tamoxifen. The patients are divided in four equal quarters (Q1-Q4) based on their F/B tumor level. Patients at risk at various time points are indicated